Deutsch

Insider-Transaktionen

EDGAR

Natera, Inc.

Von Direktoren, Führungskräften und 10-%-Eignern auf den SEC-Formularen 3, 4 und 5 gemeldete Transaktionen, aus dem XML jeder Einreichung gelesen. Codes und ihr Wortlaut stammen von der SEC.

Das Formular 4 ist innerhalb von zwei Geschäftstagen nach der Transaktion einzureichen; die jüngsten Geschäfte sind daher möglicherweise noch nicht gemeldet.

Zeitfenster: Transaktionen ab dem 15. Nov. 2025.

Käufe am offenen Markt (Code P): 0 Transaktionen, — Aktien
Verkäufe am offenen Markt (Code S): 546 Transaktionen, 1.451.822 Aktien; Summe Aktien × Preis je Aktie: 365.591.600,4009

Die Summen addieren die aufgeführten eingereichten Transaktionen; sie zählen das Gemeldete und messen keine Richtung.

1–50 von 653 angezeigt

Insider-Transaktionen, neueste zuerst, wie auf den SEC-Formularen 3, 4 und 5 eingereicht
Datum	Meldende Person	Code	Erworben oder veräußert	Aktien	Preis je Aktie, wie eingereicht	Wert (abgeleitet)	Aktien danach im Besitz	Direkt oder indirekt	Kästchen zu Rule 10b5-1	Anmerkungen	Quelle
23. Juni 2029 Eingereicht am 25. Juni 2020	Brophy Michael Burkes Officer: Chief Financial Officer	M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Derivatives Wertpapier: Restricted Stock Units — Basiswert Common Stock (12.500)	Veräußert (D)	12.500	0	—	37.500	Direkt (D)	In dieser Formularversion nicht vorhanden	F2, F7 F2 Each RSU represents a contingent right to receive one share of the common stock of the issuer. F7 On March 22, 2019, the Reporting Person was granted RSUs covering 100,000 shares of common stock, which vests in tranches upon the Reporting Person achieving certain milestones relating to a combination of the passage of time and the Reporting Person achieving certain milestones relating to the Issuer's stock price, based on the average closing price per share of the Issuer's common stock for a calendar month, calculated as of the last day of such calendar month. On June 23, 2020, the criteria was satisfied for the vesting of RSUs covering 12,500 shares of common stock.	Einreichung öffnen 0001179110-20-007780 Aus dem XML der Einreichung gelesen Diese Zeile anfechten
8. Juni 2029 Eingereicht am 10. Juni 2020	Brophy Michael Burkes Officer: Chief Financial Officer	M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Derivatives Wertpapier: Restricted Stock Units — Basiswert Common Stock (25.000)	Veräußert (D)	25.000	0	—	50.000	Direkt (D)	In dieser Formularversion nicht vorhanden	F2, F6 F2 Each RSU represents a contingent right to receive one share of the common stock of the issuer. F6 On March 22, 2019, the Reporting Person was granted RSUs covering 100,000 shares of common stock, which vests in tranches upon the Reporting Person achieving certain milestones relating to a combination of the passage of time and the Reporting Person achieving certain milestones relating to the Issuer's stock price, based on the average closing price per share of the Issuer's common stock for a calendar month, calculated as of the last day of such calendar month. On June 8, 2020, the criteria was satisfied for the vesting of RSUs covering 25,000 shares of common stock.	Einreichung öffnen 0001179110-20-007206 Aus dem XML der Einreichung gelesen Diese Zeile anfechten
11. Nov. 2026 Eingereicht am 13. Nov. 2026	Sheena Jonathan Director · Other: CO-FOUNDER	S Open market or private sale of non-derivative or derivative security Common Stock	Veräußert (D)	40	315,26	12.610,4 Abgeleitet: Aktien × Preis je Aktie. Exakter Wert 12610.40.	8.210	Indirekt (I) by Caraluna 1 Trust	Ja	F1, F2 F1 The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 11, 2026. F2 Held for the benefit of the beneficiaries of the trust. The Reporting Person disclaims beneficial ownership over such securities.	Einreichung öffnen 0001646649-26-000045 Aus dem XML der Einreichung gelesen Diese Zeile anfechten
11. Nov. 2026 Eingereicht am 13. Nov. 2026	Sheena Jonathan Director · Other: CO-FOUNDER	S Open market or private sale of non-derivative or derivative security Common Stock	Veräußert (D)	85	316,9256	26.938,676 Abgeleitet: Aktien × Preis je Aktie. Exakter Wert 26938.6760.	8.125	Indirekt (I) By Caraluna 1 Trust	Ja	F1, F3, F2 F1 The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 11, 2026. F3 The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $316.4100 to $317.4050 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 Held for the benefit of the beneficiaries of the trust. The Reporting Person disclaims beneficial ownership over such securities.	Einreichung öffnen 0001646649-26-000045 Aus dem XML der Einreichung gelesen Diese Zeile anfechten
11. Nov. 2026 Eingereicht am 13. Nov. 2026	Sheena Jonathan Director · Other: CO-FOUNDER	S Open market or private sale of non-derivative or derivative security Common Stock	Veräußert (D)	145	317,8748	46.091,846 Abgeleitet: Aktien × Preis je Aktie. Exakter Wert 46091.8460.	7.980	Indirekt (I) By Caraluna 1 Trust	Ja	F1, F4, F2 F1 The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 11, 2026. F4 The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $317.56 to $318.17 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 Held for the benefit of the beneficiaries of the trust. The Reporting Person disclaims beneficial ownership over such securities.	Einreichung öffnen 0001646649-26-000045 Aus dem XML der Einreichung gelesen Diese Zeile anfechten
11. Nov. 2026 Eingereicht am 13. Nov. 2026	Sheena Jonathan Director · Other: CO-FOUNDER	S Open market or private sale of non-derivative or derivative security Common Stock	Veräußert (D)	240	319,7733	76.745,592 Abgeleitet: Aktien × Preis je Aktie. Exakter Wert 76745.5920.	7.740	Indirekt (I) By Caraluna 1 Trust	Ja	F1, F5, F2 F1 The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 11, 2026. F5 The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $318.8350 to $319.5250 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 Held for the benefit of the beneficiaries of the trust. The Reporting Person disclaims beneficial ownership over such securities.	Einreichung öffnen 0001646649-26-000045 Aus dem XML der Einreichung gelesen Diese Zeile anfechten
11. Nov. 2026 Eingereicht am 13. Nov. 2026	Sheena Jonathan Director · Other: CO-FOUNDER	S Open market or private sale of non-derivative or derivative security Common Stock	Veräußert (D)	160	320,0188	51.203,008 Abgeleitet: Aktien × Preis je Aktie. Exakter Wert 51203.0080.	7.580	Indirekt (I) By Caraluna 1 Trust	Ja	F1, F6, F2 F1 The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 11, 2026. F6 The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $319.87 to $320.26 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 Held for the benefit of the beneficiaries of the trust. The Reporting Person disclaims beneficial ownership over such securities.	Einreichung öffnen 0001646649-26-000045 Aus dem XML der Einreichung gelesen Diese Zeile anfechten
11. Nov. 2026 Eingereicht am 13. Nov. 2026	Sheena Jonathan Director · Other: CO-FOUNDER	S Open market or private sale of non-derivative or derivative security Common Stock	Veräußert (D)	40	322	12.880 Abgeleitet: Aktien × Preis je Aktie. Exakter Wert 12880.	7.540	Indirekt (I) By Caraluna 1 Trust	Ja	F1, F2 F1 The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 11, 2026. F2 Held for the benefit of the beneficiaries of the trust. The Reporting Person disclaims beneficial ownership over such securities.	Einreichung öffnen 0001646649-26-000045 Aus dem XML der Einreichung gelesen Diese Zeile anfechten
11. Nov. 2026 Eingereicht am 13. Nov. 2026	Sheena Jonathan Director · Other: CO-FOUNDER	S Open market or private sale of non-derivative or derivative security Common Stock	Veräußert (D)	40	323,0650	12.922,6 Abgeleitet: Aktien × Preis je Aktie. Exakter Wert 12922.6000.	7.500	Indirekt (I) By Caraluna 1 Trust	Ja	F1, F2 F1 The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 11, 2026. F2 Held for the benefit of the beneficiaries of the trust. The Reporting Person disclaims beneficial ownership over such securities.	Einreichung öffnen 0001646649-26-000045 Aus dem XML der Einreichung gelesen Diese Zeile anfechten
11. Nov. 2026 Eingereicht am 13. Nov. 2026	Sheena Jonathan Director · Other: CO-FOUNDER	S Open market or private sale of non-derivative or derivative security Common Stock	Veräußert (D)	40	315,28	12.611,2 Abgeleitet: Aktien × Preis je Aktie. Exakter Wert 12611.20.	8.210	Indirekt (I) By Caraluna 2 Trust	Ja	F1, F2 F1 The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 11, 2026. F2 Held for the benefit of the beneficiaries of the trust. The Reporting Person disclaims beneficial ownership over such securities.	Einreichung öffnen 0001646649-26-000045 Aus dem XML der Einreichung gelesen Diese Zeile anfechten
11. Nov. 2026 Eingereicht am 13. Nov. 2026	Sheena Jonathan Director · Other: CO-FOUNDER	S Open market or private sale of non-derivative or derivative security Common Stock	Veräußert (D)	48	317,3253	15.231,6144 Abgeleitet: Aktien × Preis je Aktie. Exakter Wert 15231.6144.	8.162	Indirekt (I) By Caraluna 2 Trust	Ja	F1, F7, F2 F1 The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 11, 2026. F7 The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $316.5200 to $317.4050 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 Held for the benefit of the beneficiaries of the trust. The Reporting Person disclaims beneficial ownership over such securities.	Einreichung öffnen 0001646649-26-000045 Aus dem XML der Einreichung gelesen Diese Zeile anfechten
11. Nov. 2026 Eingereicht am 13. Nov. 2026	Sheena Jonathan Director · Other: CO-FOUNDER	S Open market or private sale of non-derivative or derivative security Common Stock	Veräußert (D)	182	317,9626	57.869,1932 Abgeleitet: Aktien × Preis je Aktie. Exakter Wert 57869.1932.	7.980	Indirekt (I) By Caraluna 2 Trust	Ja	F1, F8, F2 F1 The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 11, 2026. F8 The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $317.56 to $318.31 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 Held for the benefit of the beneficiaries of the trust. The Reporting Person disclaims beneficial ownership over such securities.	Einreichung öffnen 0001646649-26-000045 Aus dem XML der Einreichung gelesen Diese Zeile anfechten
11. Nov. 2026 Eingereicht am 13. Nov. 2026	Sheena Jonathan Director · Other: CO-FOUNDER	S Open market or private sale of non-derivative or derivative security Common Stock	Veräußert (D)	240	319,2167	76.612,008 Abgeleitet: Aktien × Preis je Aktie. Exakter Wert 76612.0080.	7.740	Indirekt (I) By Caraluna 2 Trust	Ja	F1, F9, F2 F1 The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 11, 2026. F9 The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $318.8350 to $319.5500 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 Held for the benefit of the beneficiaries of the trust. The Reporting Person disclaims beneficial ownership over such securities.	Einreichung öffnen 0001646649-26-000045 Aus dem XML der Einreichung gelesen Diese Zeile anfechten
11. Nov. 2026 Eingereicht am 13. Nov. 2026	Sheena Jonathan Director · Other: CO-FOUNDER	S Open market or private sale of non-derivative or derivative security Common Stock	Veräußert (D)	120	320,0683	38.408,196 Abgeleitet: Aktien × Preis je Aktie. Exakter Wert 38408.1960.	7.620	Indirekt (I) By Caraluna 2 Trust	Ja	F1, F10, F2 F1 The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 11, 2026. F10 The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $319.9450 to $320.2600 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 Held for the benefit of the beneficiaries of the trust. The Reporting Person disclaims beneficial ownership over such securities.	Einreichung öffnen 0001646649-26-000045 Aus dem XML der Einreichung gelesen Diese Zeile anfechten
11. Nov. 2026 Eingereicht am 13. Nov. 2026	Sheena Jonathan Director · Other: CO-FOUNDER	S Open market or private sale of non-derivative or derivative security Common Stock	Veräußert (D)	80	322,8750	25.830 Abgeleitet: Aktien × Preis je Aktie. Exakter Wert 25830.0000.	7.540	Indirekt (I) By Caraluna 2 Trust	Ja	F1, F11, F2 F1 The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 11, 2026. F11 The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $322.62 to $323.13 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 Held for the benefit of the beneficiaries of the trust. The Reporting Person disclaims beneficial ownership over such securities.	Einreichung öffnen 0001646649-26-000045 Aus dem XML der Einreichung gelesen Diese Zeile anfechten
11. Nov. 2026 Eingereicht am 13. Nov. 2026	Sheena Jonathan Director · Other: CO-FOUNDER	S Open market or private sale of non-derivative or derivative security Common Stock	Veräußert (D)	40	324,76	12.990,4 Abgeleitet: Aktien × Preis je Aktie. Exakter Wert 12990.40.	7.500	Indirekt (I) By Caraluna 2 Trust	Ja	F1, F2 F1 The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 11, 2026. F2 Held for the benefit of the beneficiaries of the trust. The Reporting Person disclaims beneficial ownership over such securities.	Einreichung öffnen 0001646649-26-000045 Aus dem XML der Einreichung gelesen Diese Zeile anfechten
6. Nov. 2026 Eingereicht am 10. Nov. 2026	Sheena Jonathan Director · Other: CO-FOUNDER	S Open market or private sale of non-derivative or derivative security Common Stock	Veräußert (D)	15	304,5713	4.568,5695 Abgeleitet: Aktien × Preis je Aktie. Exakter Wert 4568.5695.	217.597	Direkt (D)	Ja	F1, F2, F3 F1 The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 12, 2025. F2 The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $304.24 to $304.95 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 Includes 38 shares acquired under the Issuer's 2015 Employee Stock Purchase Plan on October 31, 2026	Einreichung öffnen 0001646649-26-000044 Aus dem XML der Einreichung gelesen Diese Zeile anfechten
6. Nov. 2026 Eingereicht am 10. Nov. 2026	Sheena Jonathan Director · Other: CO-FOUNDER	S Open market or private sale of non-derivative or derivative security Common Stock	Veräußert (D)	51	305,7527	15.593,3877 Abgeleitet: Aktien × Preis je Aktie. Exakter Wert 15593.3877.	217.546	Direkt (D)	Ja	F1, F4 F1 The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 12, 2025. F4 The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $305.30 to $306.24 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.	Einreichung öffnen 0001646649-26-000044 Aus dem XML der Einreichung gelesen Diese Zeile anfechten
6. Nov. 2026 Eingereicht am 10. Nov. 2026	Sheena Jonathan Director · Other: CO-FOUNDER	S Open market or private sale of non-derivative or derivative security Common Stock	Veräußert (D)	21	306,4633	6.435,7293 Abgeleitet: Aktien × Preis je Aktie. Exakter Wert 6435.7293.	217.525	Direkt (D)	Ja	F1, F5 F1 The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 12, 2025. F5 The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $306.39 to $306.50 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.	Einreichung öffnen 0001646649-26-000044 Aus dem XML der Einreichung gelesen Diese Zeile anfechten
6. Nov. 2026 Eingereicht am 10. Nov. 2026	Sheena Jonathan Director · Other: CO-FOUNDER	S Open market or private sale of non-derivative or derivative security Common Stock	Veräußert (D)	50	308,1980	15.409,9 Abgeleitet: Aktien × Preis je Aktie. Exakter Wert 15409.9000.	217.475	Direkt (D)	Ja	F1, F6 F1 The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 12, 2025. F6 The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $307.70 to $308.54 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.	Einreichung öffnen 0001646649-26-000044 Aus dem XML der Einreichung gelesen Diese Zeile anfechten
6. Nov. 2026 Eingereicht am 10. Nov. 2026	Sheena Jonathan Director · Other: CO-FOUNDER	S Open market or private sale of non-derivative or derivative security Common Stock	Veräußert (D)	64	309,0817	19.781,2288 Abgeleitet: Aktien × Preis je Aktie. Exakter Wert 19781.2288.	217.411	Direkt (D)	Ja	F1, F7 F1 The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 12, 2025. F7 The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $308.7200 to $309.6450 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.	Einreichung öffnen 0001646649-26-000044 Aus dem XML der Einreichung gelesen Diese Zeile anfechten
6. Nov. 2026 Eingereicht am 10. Nov. 2026	Sheena Jonathan Director · Other: CO-FOUNDER	S Open market or private sale of non-derivative or derivative security Common Stock	Veräußert (D)	110	310,1655	34.118,205 Abgeleitet: Aktien × Preis je Aktie. Exakter Wert 34118.2050.	217.301	Direkt (D)	Ja	F1, F8 F1 The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 12, 2025. F8 The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $309.81 to $310.66 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.	Einreichung öffnen 0001646649-26-000044 Aus dem XML der Einreichung gelesen Diese Zeile anfechten
6. Nov. 2026 Eingereicht am 10. Nov. 2026	Sheena Jonathan Director · Other: CO-FOUNDER	S Open market or private sale of non-derivative or derivative security Common Stock	Veräußert (D)	100	311,3116	31.131,16 Abgeleitet: Aktien × Preis je Aktie. Exakter Wert 31131.1600.	217.201	Direkt (D)	Ja	F1, F9 F1 The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 12, 2025. F9 The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $310.99 to $311.98 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.	Einreichung öffnen 0001646649-26-000044 Aus dem XML der Einreichung gelesen Diese Zeile anfechten
6. Nov. 2026 Eingereicht am 10. Nov. 2026	Sheena Jonathan Director · Other: CO-FOUNDER	S Open market or private sale of non-derivative or derivative security Common Stock	Veräußert (D)	106	312,1965	33.092,829 Abgeleitet: Aktien × Preis je Aktie. Exakter Wert 33092.8290.	217.095	Direkt (D)	Ja	F1, F10 F1 The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 12, 2025. F10 The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $312.00 to $312.46 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.	Einreichung öffnen 0001646649-26-000044 Aus dem XML der Einreichung gelesen Diese Zeile anfechten
6. Nov. 2026 Eingereicht am 10. Nov. 2026	Sheena Jonathan Director · Other: CO-FOUNDER	S Open market or private sale of non-derivative or derivative security Common Stock	Veräußert (D)	74	313,3168	23.185,4432 Abgeleitet: Aktien × Preis je Aktie. Exakter Wert 23185.4432.	217.021	Direkt (D)	Ja	F1, F11 F1 The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 12, 2025. F11 The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $313.01 to $314.00 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.	Einreichung öffnen 0001646649-26-000044 Aus dem XML der Einreichung gelesen Diese Zeile anfechten
6. Nov. 2026 Eingereicht am 10. Nov. 2026	Sheena Jonathan Director · Other: CO-FOUNDER	S Open market or private sale of non-derivative or derivative security Common Stock	Veräußert (D)	108	314,7084	33.988,5072 Abgeleitet: Aktien × Preis je Aktie. Exakter Wert 33988.5072.	216.913	Direkt (D)	Ja	F1, F12 F1 The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 12, 2025. F12 The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $314.04 to $315.01 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.	Einreichung öffnen 0001646649-26-000044 Aus dem XML der Einreichung gelesen Diese Zeile anfechten
6. Nov. 2026 Eingereicht am 10. Nov. 2026	Sheena Jonathan Director · Other: CO-FOUNDER	S Open market or private sale of non-derivative or derivative security Common Stock	Veräußert (D)	169	315,4827	53.316,5763 Abgeleitet: Aktien × Preis je Aktie. Exakter Wert 53316.5763.	216.744	Direkt (D)	Ja	F1, F13 F1 The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 12, 2025. F13 The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $315.0900 to $316.0750 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.	Einreichung öffnen 0001646649-26-000044 Aus dem XML der Einreichung gelesen Diese Zeile anfechten
6. Nov. 2026 Eingereicht am 10. Nov. 2026	Sheena Jonathan Director · Other: CO-FOUNDER	S Open market or private sale of non-derivative or derivative security Common Stock	Veräußert (D)	1.838	316,8674	582.402,2812 Abgeleitet: Aktien × Preis je Aktie. Exakter Wert 582402.2812.	214.906	Direkt (D)	Ja	F1, F14 F1 The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 12, 2025. F14 The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $316.24 to $317.14 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.	Einreichung öffnen 0001646649-26-000044 Aus dem XML der Einreichung gelesen Diese Zeile anfechten
6. Nov. 2026 Eingereicht am 10. Nov. 2026	Sheena Jonathan Director · Other: CO-FOUNDER	S Open market or private sale of non-derivative or derivative security Common Stock	Veräußert (D)	56	318,1661	17.817,3016 Abgeleitet: Aktien × Preis je Aktie. Exakter Wert 17817.3016.	214.850	Direkt (D)	Ja	F1, F15 F1 The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 12, 2025. F15 The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $317.36 to $318.30 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.	Einreichung öffnen 0001646649-26-000044 Aus dem XML der Einreichung gelesen Diese Zeile anfechten
6. Nov. 2026 Eingereicht am 10. Nov. 2026	Sheena Jonathan Director · Other: CO-FOUNDER	S Open market or private sale of non-derivative or derivative security Common Stock	Veräußert (D)	105	319,2993	33.526,4265 Abgeleitet: Aktien × Preis je Aktie. Exakter Wert 33526.4265.	214.745	Direkt (D)	Ja	F1, F16 F1 The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 12, 2025. F16 The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $318.67 to $319.66 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.	Einreichung öffnen 0001646649-26-000044 Aus dem XML der Einreichung gelesen Diese Zeile anfechten
6. Nov. 2026 Eingereicht am 10. Nov. 2026	Sheena Jonathan Director · Other: CO-FOUNDER	S Open market or private sale of non-derivative or derivative security Common Stock	Veräußert (D)	131	320,0673	41.928,8163 Abgeleitet: Aktien × Preis je Aktie. Exakter Wert 41928.8163.	214.614	Direkt (D)	Ja	F1, F17 F1 The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 12, 2025. F17 The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $319.67 to $320.54 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.	Einreichung öffnen 0001646649-26-000044 Aus dem XML der Einreichung gelesen Diese Zeile anfechten
6. Nov. 2026 Eingereicht am 10. Nov. 2026	Sheena Jonathan Director · Other: CO-FOUNDER	S Open market or private sale of non-derivative or derivative security Common Stock	Veräußert (D)	51	321,1191	16.377,0741 Abgeleitet: Aktien × Preis je Aktie. Exakter Wert 16377.0741.	214.563	Direkt (D)	Ja	F1, F18 F1 The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 12, 2025. F18 The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $320.77 to $321.63 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.	Einreichung öffnen 0001646649-26-000044 Aus dem XML der Einreichung gelesen Diese Zeile anfechten
6. Nov. 2026 Eingereicht am 10. Nov. 2026	Sheena Jonathan Director · Other: CO-FOUNDER	S Open market or private sale of non-derivative or derivative security Common Stock	Veräußert (D)	16	321,85	5.149,6 Abgeleitet: Aktien × Preis je Aktie. Exakter Wert 5149.60.	214.547	Direkt (D)	Ja	F1 F1 The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 12, 2025.	Einreichung öffnen 0001646649-26-000044 Aus dem XML der Einreichung gelesen Diese Zeile anfechten
6. Nov. 2026 Eingereicht am 10. Nov. 2026	Sheena Jonathan Director · Other: CO-FOUNDER	S Open market or private sale of non-derivative or derivative security Common Stock	Veräußert (D)	40	323,8590	12.954,36 Abgeleitet: Aktien × Preis je Aktie. Exakter Wert 12954.3600.	214.507	Direkt (D)	Ja	F1, F19 F1 The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 12, 2025. F19 The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $323.3800 to $324.3550 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.	Einreichung öffnen 0001646649-26-000044 Aus dem XML der Einreichung gelesen Diese Zeile anfechten
6. Nov. 2026 Eingereicht am 10. Nov. 2026	Sheena Jonathan Director · Other: CO-FOUNDER	S Open market or private sale of non-derivative or derivative security Common Stock	Veräußert (D)	45	325,0509	14.627,2905 Abgeleitet: Aktien × Preis je Aktie. Exakter Wert 14627.2905.	214.462	Direkt (D)	Ja	F1, F20 F1 The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 12, 2025. F20 The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $324.56 to $325.53 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.	Einreichung öffnen 0001646649-26-000044 Aus dem XML der Einreichung gelesen Diese Zeile anfechten
3. Nov. 2026 Eingereicht am 4. Nov. 2026	Brophy Michael Burkes Officer: CHIEF FINANCIAL OFFICER	S Open market or private sale of non-derivative or derivative security Common Stock	Veräußert (D)	470	391,49	184.000,3 Abgeleitet: Aktien × Preis je Aktie. Exakter Wert 184000.30.	45.779	Direkt (D)	Ja	F2 F2 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 9, 2025, as modified on September 10, 2025.	Einreichung öffnen 0001697362-26-000024 Aus dem XML der Einreichung gelesen Diese Zeile anfechten
2. Nov. 2026 Eingereicht am 4. Nov. 2026	Fesko John Officer: PRESIDENT, CHIEF BUS. OFFICER	S Open market or private sale of non-derivative or derivative security Common Stock	Veräußert (D)	7	388,2001	2.717,4007 Abgeleitet: Aktien × Preis je Aktie. Exakter Wert 2717.4007.	195.571	Direkt (D)	Ja	F1 F1 The sale of shares was effected in order to satisfy tax withholding and remittance obligations in connection with the vesting of RSUs and was made pursuant to a written instruction that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act contained in the Reporting Person's Stock Unit Agreement granted on January 31, 2025.	Einreichung öffnen 0002010135-26-000028 Aus dem XML der Einreichung gelesen Diese Zeile anfechten
2. Nov. 2026 Eingereicht am 4. Nov. 2026	Fesko John Officer: PRESIDENT, CHIEF BUS. OFFICER	S Open market or private sale of non-derivative or derivative security Common Stock	Veräußert (D)	295	400,2942	118.086,789 Abgeleitet: Aktien × Preis je Aktie. Exakter Wert 118086.7890.	195.276	Direkt (D)	Ja	F1 F1 The sale of shares was effected in order to satisfy tax withholding and remittance obligations in connection with the vesting of RSUs and was made pursuant to a written instruction that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act contained in the Reporting Person's Stock Unit Agreement granted on January 31, 2025.	Einreichung öffnen 0002010135-26-000028 Aus dem XML der Einreichung gelesen Diese Zeile anfechten
2. Nov. 2026 Eingereicht am 4. Nov. 2026	Rabinowitz Matthew Director · Officer: EXECUTIVE CHAIRMAN	S Open market or private sale of non-derivative or derivative security Common Stock	Veräußert (D)	17	388,20	6.599,4 Abgeleitet: Aktien × Preis je Aktie. Exakter Wert 6599.40.	2.117.659	Direkt (D)	Ja	F1 F1 The sale of shares was effected in order to satisfy tax withholding and remittance obligations in connection with the vesting of RSUs and was made pursuant to a written instruction that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act contained in the Reporting Person's Stock Unit Agreement granted on January 31, 2025.	Einreichung öffnen 0001646382-26-000029 Aus dem XML der Einreichung gelesen Diese Zeile anfechten
2. Nov. 2026 Eingereicht am 4. Nov. 2026	Rabinowitz Matthew Director · Officer: EXECUTIVE CHAIRMAN	S Open market or private sale of non-derivative or derivative security Common Stock	Veräußert (D)	731	400,2942	292.615,0602 Abgeleitet: Aktien × Preis je Aktie. Exakter Wert 292615.0602.	2.116.928	Direkt (D)	Ja	F1 F1 The sale of shares was effected in order to satisfy tax withholding and remittance obligations in connection with the vesting of RSUs and was made pursuant to a written instruction that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act contained in the Reporting Person's Stock Unit Agreement granted on January 31, 2025.	Einreichung öffnen 0001646382-26-000029 Aus dem XML der Einreichung gelesen Diese Zeile anfechten
2. Nov. 2026 Eingereicht am 4. Nov. 2026	Sheena Jonathan Director · Other: CO-FOUNDER	S Open market or private sale of non-derivative or derivative security Common Stock	Veräußert (D)	3	388,20	1.164,6 Abgeleitet: Aktien × Preis je Aktie. Exakter Wert 1164.60.	217.683	Direkt (D)	Ja	F1 F1 The sale of shares was effected in order to satisfy tax withholding and remittance obligations in connection with the vesting of RSUs and was made pursuant to a written instruction that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act contained in the Reporting Person's Stock Unit Agreement granted on January 31, 2025.	Einreichung öffnen 0001646649-26-000043 Aus dem XML der Einreichung gelesen Diese Zeile anfechten
2. Nov. 2026 Eingereicht am 4. Nov. 2026	Sheena Jonathan Director · Other: CO-FOUNDER	S Open market or private sale of non-derivative or derivative security Common Stock	Veräußert (D)	109	400,2942	43.632,0678 Abgeleitet: Aktien × Preis je Aktie. Exakter Wert 43632.0678.	217.574	Direkt (D)	Ja	F1 F1 The sale of shares was effected in order to satisfy tax withholding and remittance obligations in connection with the vesting of RSUs and was made pursuant to a written instruction that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act contained in the Reporting Person's Stock Unit Agreement granted on January 31, 2025.	Einreichung öffnen 0001646649-26-000043 Aus dem XML der Einreichung gelesen Diese Zeile anfechten
2. Nov. 2026 Eingereicht am 4. Nov. 2026	Brophy Michael Burkes Officer: CHIEF FINANCIAL OFFICER	S Open market or private sale of non-derivative or derivative security Common Stock	Veräußert (D)	8	388,0301	3.104,2408 Abgeleitet: Aktien × Preis je Aktie. Exakter Wert 3104.2408.	46.566	Direkt (D)	Ja	F1 F1 The sale of shares was effected in order to satisfy tax withholding and remittance obligations in connection with the vesting of Restricted Stock Units (RSUs) and was made pursuant to a written instruction that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act contained in the Reporting Person's Stock Unit Agreement granted on January 31, 2025.	Einreichung öffnen 0001697362-26-000024 Aus dem XML der Einreichung gelesen Diese Zeile anfechten
2. Nov. 2026 Eingereicht am 4. Nov. 2026	Brophy Michael Burkes Officer: CHIEF FINANCIAL OFFICER	S Open market or private sale of non-derivative or derivative security Common Stock	Veräußert (D)	317	400,2942	126.893,2614 Abgeleitet: Aktien × Preis je Aktie. Exakter Wert 126893.2614.	46.249	Direkt (D)	Ja	F1 F1 The sale of shares was effected in order to satisfy tax withholding and remittance obligations in connection with the vesting of Restricted Stock Units (RSUs) and was made pursuant to a written instruction that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act contained in the Reporting Person's Stock Unit Agreement granted on January 31, 2025.	Einreichung öffnen 0001697362-26-000024 Aus dem XML der Einreichung gelesen Diese Zeile anfechten
2. Nov. 2026 Eingereicht am 4. Nov. 2026	RABINOWITZ DANIEL Officer: SEC. AND CHIEF LEGAL OFFICER	S Open market or private sale of non-derivative or derivative security Common Stock	Veräußert (D)	7	388,20	2.717,4 Abgeleitet: Aktien × Preis je Aktie. Exakter Wert 2717.40.	168.214	Direkt (D)	Ja	F1 F1 The sale of shares was effected in order to satisfy tax withholding and remittance obligations in connection with the vesting of RSUs and was made pursuant to a written instruction that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act contained in the Reporting Person's Stock Unit Agreement granted on January 31, 2025.	Einreichung öffnen 0001857843-26-000033 Aus dem XML der Einreichung gelesen Diese Zeile anfechten
2. Nov. 2026 Eingereicht am 4. Nov. 2026	RABINOWITZ DANIEL Officer: SEC. AND CHIEF LEGAL OFFICER	S Open market or private sale of non-derivative or derivative security Common Stock	Veräußert (D)	334	400,2942	133.698,2628 Abgeleitet: Aktien × Preis je Aktie. Exakter Wert 133698.2628.	167.880	Direkt (D)	Ja	F1 F1 The sale of shares was effected in order to satisfy tax withholding and remittance obligations in connection with the vesting of RSUs and was made pursuant to a written instruction that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act contained in the Reporting Person's Stock Unit Agreement granted on January 31, 2025.	Einreichung öffnen 0001857843-26-000033 Aus dem XML der Einreichung gelesen Diese Zeile anfechten
2. Nov. 2026 Eingereicht am 4. Nov. 2026	Moshkevich Solomon Officer: PRESIDENT, CLINICALDIAGNOSTICS	S Open market or private sale of non-derivative or derivative security Common Stock	Veräußert (D)	9	388,2001	3.493,8009 Abgeleitet: Aktien × Preis je Aktie. Exakter Wert 3493.8009.	104.733	Direkt (D)	Ja	F1 F1 The sale of shares was effected in order to satisfy tax withholding and remittance obligations in connection with the vesting of RSUs and was made pursuant to a written instruction that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act contained in the Reporting Person's Stock Unit Agreement granted on January 31, 2025.	Einreichung öffnen 0002010019-26-000038 Aus dem XML der Einreichung gelesen Diese Zeile anfechten
2. Nov. 2026 Eingereicht am 4. Nov. 2026	Moshkevich Solomon Officer: PRESIDENT, CLINICALDIAGNOSTICS	S Open market or private sale of non-derivative or derivative security Common Stock	Veräußert (D)	410	400,2942	164.120,622 Abgeleitet: Aktien × Preis je Aktie. Exakter Wert 164120.6220.	104.323	Direkt (D)	Ja	F1 F1 The sale of shares was effected in order to satisfy tax withholding and remittance obligations in connection with the vesting of RSUs and was made pursuant to a written instruction that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act contained in the Reporting Person's Stock Unit Agreement granted on January 31, 2025.	Einreichung öffnen 0002010019-26-000038 Aus dem XML der Einreichung gelesen Diese Zeile anfechten
2. Nov. 2026 Eingereicht am 4. Nov. 2026	Moshkevich Solomon Officer: PRESIDENT, CLINICALDIAGNOSTICS	S Open market or private sale of non-derivative or derivative security Common Stock	Veräußert (D)	200	405,2560	81.051,2 Abgeleitet: Aktien × Preis je Aktie. Exakter Wert 81051.2000.	104.123	Direkt (D)	Ja	F2, F3 F2 The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 26, 2024. F3 The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $404.8500 to $405.8450 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.	Einreichung öffnen 0002010019-26-000038 Aus dem XML der Einreichung gelesen Diese Zeile anfechten
2. Nov. 2026 Eingereicht am 4. Nov. 2026	Moshkevich Solomon Officer: PRESIDENT, CLINICALDIAGNOSTICS	S Open market or private sale of non-derivative or derivative security Common Stock	Veräußert (D)	432	406,9398	175.797,9936 Abgeleitet: Aktien × Preis je Aktie. Exakter Wert 175797.9936.	103.691	Direkt (D)	Ja	F2, F4 F2 The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 26, 2024. F4 The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $406.4150 to $407.3750 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.	Einreichung öffnen 0002010019-26-000038 Aus dem XML der Einreichung gelesen Diese Zeile anfechten

Institutionelle Halter (Formular 13F)

Im Speicher ist dieser Emittent keiner Form-13F-Position zugeordnet. Ein noch nicht verknüpfter oder noch nicht meldender Halter fehlt, er steht nicht bei null.

5-%-Halter (Schedule 13D und 13G)

Hier werden im strukturierten SEC-Format (ab Ende 2024) eingereichte Schedules gelesen. Frühere sind Freitext und werden nicht gelesen.

5-%-Halter, jüngstes Ereignis zuerst, wie eingereicht
Halter	Prozent der Gattung	Gehaltene Aktien	Ereignisdatum	Formular	Quelle
FMR LLC COMMON STOCK	10.5	15.131.244,72	10/30/2026 Eingereicht am 6. Nov. 2026	SCHEDULE 13G/AÄnderung 1	Einreichung öffnen 0000315066-26-002940 Diese Zeile anfechten
Abigail P. Johnson COMMON STOCK	10.5	15.131.244,72	10/30/2026 Eingereicht am 6. Nov. 2026	SCHEDULE 13G/AÄnderung 1	Einreichung öffnen 0000315066-26-002940 Diese Zeile anfechten
FMR LLC COMMON STOCK	9.5	13.659.508,25	09/30/2026 Eingereicht am 5. Nov. 2026	SCHEDULE 13G	Einreichung öffnen 0000315066-26-002810 Diese Zeile anfechten
Abigail P. Johnson COMMON STOCK	9.5	13.659.508,25	09/30/2026 Eingereicht am 5. Nov. 2026	SCHEDULE 13G	Einreichung öffnen 0000315066-26-002810 Diese Zeile anfechten
T. Rowe Price Associates, Inc. COMMON STOCK	6.3	9.021.825	06/30/2026 Eingereicht am 14. Aug. 2026	SCHEDULE 13G/AÄnderung 4	Einreichung öffnen 0000080255-26-000548 Diese Zeile anfechten
Vanguard Capital Management Common Stock	5.08	7.205.939	03/31/2026 Eingereicht am 30. Apr. 2026	SCHEDULE 13G	Einreichung öffnen 0002100119-26-000780 Diese Zeile anfechten
The Vanguard Group Common Stock	0	0	03/13/2026 Eingereicht am 27. März 2026	SCHEDULE 13G/AÄnderung 7	Einreichung öffnen 0000102909-26-001882 Diese Zeile anfechten
T. Rowe Price Associates, Inc. COMMON STOCK	7.8	10.872.702	12/31/2025 Eingereicht am 17. Feb. 2026	SCHEDULE 13G/AÄnderung 3	Einreichung öffnen 0000080255-26-000263 Diese Zeile anfechten
JPMORGAN CHASE CO. Common Stock, par value $0.0001 per share	9.1	12.825.640	12/31/2025 Eingereicht am 23. Jan. 2026	SCHEDULE 13G/AÄnderung 2	Einreichung öffnen 0000019617-26-000064 Diese Zeile anfechten
T. Rowe Price Associates, Inc. COMMON STOCK	8.9	12.191.814	06/30/2025 Eingereicht am 14. Aug. 2025	SCHEDULE 13G/AÄnderung 2	Einreichung öffnen 0000080255-25-000584 Diese Zeile anfechten
JPMORGAN CHASE CO. Common Stock, par value $0.0001 per share	7.7	10.594.256	06/30/2025 Eingereicht am 22. Juli 2025	SCHEDULE 13G/AÄnderung 1	Einreichung öffnen 0000019617-25-000544 Diese Zeile anfechten

Der Prozentsatz bezieht sich auf die in der Einreichung genannte Gattung, wie vom Halter angegeben. Gruppenmitglieder melden jeweils die Aktien der Gruppe; die Zeilen werden daher nicht addiert.

Was gelesen wurde

2.024.280 Einreichungen gelesen, vom 14. Juni 2004 bis 13. Nov. 2026: Formulare 3, 3/A, 4, 4/A, 5, 5/A.

Jahre können unvollständig sein, solange das Archiv noch gelesen wird. Ein Jahr mit wenigen Einreichungen hier besagt nicht, dass wenige gemacht wurden.

Gelesene Einreichungen nach Einreichungsjahr
Einreichungsjahr	Gelesene Einreichungen
2015	1
2016	204.322
2017	202.494
2018	202.048
2019	193.638
2020	144.184
2021	224.474
2022	40.015
2023	199.811
2024	117.969
2025	235.520
2026	254.026

Einreichungen aus der Zeit vor der XML-Pflicht der SEC sind aufgeführt, aber nicht ausgelesen.

Zurück zu Natera, Inc.